



Antihypertensive Drug Use and the Risk of Depression: A Systematic Review and Network Meta-analysis

Ying Li^{1†}, Yuanming Fan^{1†}, Yangyang Sun¹, Raphael N. Alolga¹, Pingxi Xiao^{2*} and Gaoxiang Ma^{1*}

China, ²Department of Cardiology, Sir Run Run Hospital, Nanjing Medical University, Nanjing, China.

OPEN ACCESS

Edited by:

Peng Li, Nanjing Medical University, China

Reviewed by:

Yixin Wang, Harvard University, United States Peng Song, Nanjing Drum Tower Hospital, China

*Correspondence:

Pingxi Xiao xpx@njmu.edu.cn Gaoxiang Ma gaoxiang_ma@163.com

[†]These authors have contributed equally to this work and share first authorship

Specialty section:

This article was submitted to Cardiovascular and Smooth Muscle Pharmacology, a section of the journal Frontiers in Pharmacology

Received: 16 September 2021 Accepted: 18 October 2021 Published: 08 November 2021

Citation:

Li Y, Fan Y, Sun Y, Alolga RN, Xiao P and Ma G (2021) Antihypertensive Drug Use and the Risk of Depression: A Systematic Review and Network Meta-analysis. Front. Pharmacol. 12:777987. doi: 10.3389/fphar.2021.777987 **Background:** Although numerous cohort studies have reported an association between antihypertensives use and depression, the exact effect of antihypertensives on depression remains unclear.

¹State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing,

Objective: To clarify the association between antihypertensives use and risk of depression.

Methods: We retrieved relevant literature using PubMed database until August 30, 2021. Four main classes of antihypertensives, thus, angiotensin antagonists, beta blockers, calcium channel blockers and diuretics were studied. The incidence of depression was pooled based on a single drug category. Network meta-analyses were conducted to comprehensively assess the effects of the four classes of antihypertensives on the risk of depression.

Results: A total of nine out of 9,557 studies involving 414,873 subjects were retrieved. The pooled results showed a positive association between the use of calcium channel blockers and symptoms of depression [odds ratio (OR): 1.09, 95% confidence interval (CI): 1.06–1.13], while use of the angiotensin antagonists, beta blockers and diuretics was not associated with risk of depression. Subgroup analysis suggested a significant relationship between beta blockers usage and risk of depression in cohort studies (OR:1.21, 95% CI: 1.16–1.26). The results of network meta-analysis indicated that all other three classes of drugs increased the risk of depression: angiotensin antagonists (OR: 1.30, 95% CI: 1.04–1.63), beta blockers (OR: 1.53, 95% CI: 1.22–1.91), and calcium channel blockers (OR: 1.40, 95% CI: 1.12–1.75), compared with diuretics.

Conclusion: In conclusion, our results indicate that the use of angiotensin antagonists, beta blockers and calcium channel blockers are potential risk factors of depression.

Keywords: antihypertensive medication, depression, meta-analysis, network meta-analysis, review

1

INTRODUCTION

Depression is the most common psychiatric disorder globally (Raič, 2017). Major depression is estimated to rank as the leading cause of global disease burden by 2030 (Malhi and Mann, 2018). The World Mental Health Survey across 17 countries found that on average, approximately 1 in 20 people have experienced depression (Li et al., 2015). A large number of studies focusing on the etiology of depression have been performed (Yaniv et al., 2010; Foster and McVey Neufeld, 2013; Otte et al., 2016; Cathomas et al., 2019; Beurel et al., 2020), however, the risk factors of depression remain unclear.

Several large-sized sample cohort studies have hinted on the fact that hypertension may accompany a high incidence of depression and possibly affect its treatment and prognosis (Zhang et al., 2018). Use of antihypertensives, primarily the angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), beta blockers, calcium channel blockers and diuretics, has been implicated in depression (James et al., 20142014; Cruickshank, 2017; Agustini et al., 2020; Kessing et al., 2020).

Despite the numerous studies on the subject matter, there is still lack of clarity on whether or not antihypertensives use increases the risk of depression. Some studies have implicated antihypertensives use in depression (Nasr et al., 2011; Simonson et al., 2011; Agustini et al., 2020; Kessing et al., 2020), while others found no association between the two (Feng et al., 2008; Agustini et al., 2020). Given the large number of hypertensive subjects and the severity of depression, it is therefore justifiable to clarify the exact effect of antihypertensives on depression.

Hence, we have summarized studies to uncover the associations between antihypertensive drugs use and depression with the aim of benefitting the management of depression.

METHODS

Search Strategy and Selection Criteria

We searched the PubMed database using and expanding the MeSH terms "antihypertensive agents" and "depression" until August 30, 2021. The full search terms were illustrated in Supplementary Appendix S1. Literature retrieval was limited to human studies published in English. Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines systematic reviews were followed and fulfilled for (Supplementary Appendix S2) (Page et al., 2021). Publication that simultaneously fulfilled the following criteria were included in our study: 1) control groups were users of other classes of medication and/or nonmedicated participants; 2) studies that used a validated method to assess depression or symptoms of depression, and the measure of depression was used as a categorical variable rather than a continuous variable; and 3) studies with sample size of more than 100, so as to avoid selection bias. The selection of relevant literature was independently conducted by two researchers, and disagreements were resolved by consulting a third reviewer.

Data Extraction and Quality Assessment

For all eligible studies, two researchers independently extracted the following data: the first author, PMID, the year of publication, country, study type, sample age range, percentage of males, the methods used to define depression, odds ratio (OR) or relative risk (RR) and the corresponding 95% CI, as well as control variables for adjustment. For the analysis model used in the studies, we gave priority to multivariate analysis or adjusted OR/ RR values over univariate analysis or crude results. If the studies failed to report OR/RR, the raw data were reviewed to determine whether the OR/RR could be calculated. Different antihypertensive medication stratifications were treated as several independent results with corresponding populations separately. If there was stratification by the number of antihypertensive agents, the effect estimates were regarded as independent results separately.

The quality evaluation was assessed by two researchers independently. The Agency for Healthcare Research and Quality (AHRQ) was used to evaluate cross-sectional studies and the Newcastle-Ottawa Scale (NOS) was used for cohort studies (Rostom et al., 2004; Wells et al., 2014). The AHRQ comprised 11 items, with a scale ranging from 0 to 11 (**Supplementary Appendix S3**). Scores of 8–11 were regarded as high quality, and scores of 4–6 were regarded as moderate quality. For the NOS, an overall quality score ranged from 0 to 9 stars (**Supplementary Appendix S4**). When a study obtained more than six scores, it was regarded as high quality. When a study obtained scores of 4–6, it was regarded as moderate quality. According to the AHRQ and NOS, all studies involved were of high and moderate quality (**Supplementary Table S1**).

Statistical Analysis

In meta-analysis, the degree of heterogeneity was assessed using the I^2 statistic (Higgins et al., 2003). An I^2 value < 50% was considered an acceptable level of heterogeneity and we used the fixed effects meta-analysis model to pool data; otherwise, the random-effects model was used. The combined effect estimates were shown as pooled ORs with 95% confidence intervals (CIs) and p values. The antihypertensive drugs were divided into four groups: angiotensin antagonists, beta blockers, calcium channel blockers and diuretics. ACEI and ARB were grouped together as angiotensin antagonists. The incidence of depression was pooled based on the single drug category for all subsequent analysis. Sensitivity analysis was conducted by omitting one study each time. Publication bias was investigated using funnel plots. Subgroup analysis was performed according to the type of study (cohort/cross-sectional). To investigate the impact of confounding factors in the control group, subgroup analysis was also conducted by dividing the control group into two subgroups, with the first subgroup not taking antihypertensive medication (NoAntiHTN) as a control and the second subgroup receiving other classes of antihypertensive drugs (AntiHTN) as a reference.

The network meta-analysis was performed using the frequentist approach in the package "netmeta" (version 1.5–0) in R (version 4.1.0; https://www.r-project.org/). The random-effects model was conducted in network meta-analysis to



minimize the influence of heterogeneity. Treatments were ranked using P-score which were based solely on the point estimates and standard errors of the network estimates (Rücker and Schwarzer, 2015). Heterogeneity between studies was assessed using Cochran Q-statistics, and p value < 0.05 was considered suggestive of significant heterogeneity. Moreover, a net heat plot was employed to locate inconsistency in network meta-analysis. A comparisonadjusted funnel plot was used to assess publication bias. All statistical analyses were conducted using R version 4.1.0, with a 0.05 significance level.

RESULTS

Study Selection and Characteristics

The workflow of study selection is illustrated in **Figure 1**. In brief, a total of 9,557 publications were retrieved from the PubMed database, and 9 studies consisting 6 cross-sectional studies and 3 cohort studies were finally involved in this study (Gerstman et al., 1996; Feng et al., 2008; Simonson et al., 2011; Johansen et al.,

2012; Michal et al., 2013; Ringoir et al., 2014; Boal et al., 2016; Cao et al., 2019; Agustini et al., 2020).

Characteristics of selected publications are presented in **Table 1**. Overall 414,873 individuals were included in the final analysis. The sample sizes ranged from 573 to 181,709 individuals. Subjects were recruited from a total of 10 countries, including Australia, China, Germany, Netherlands, Norway, Singapore, the United Kingdom and the United States. Of note, the methods used to assess depression or symptoms of depression varied across the nine studies. The two main diagnostic classification systems were Diagnostic and Statistical Manual of Mental Disorders and International Classification of Diseases (Malhi and Mann, 2018). In all nine studies, three studies identified depression based on these two criteria (Gerstman et al., 1996; Simonson et al., 2011; Boal et al., 2016).

Pooled Results of the Meta-analysis

Calcium channel blockers use was significantly associated with an increased risk of depression (OR 1.09, 95% CI 1.06–1.13; **Figure 2A**). Other antihypertensive medications, including angiotensin antagonists, beta blockers and diuretics, showed

Author	Type of medication	Year	Country	Effect measures	OR (95%CI)	Age range (years)	Male (%)	Sample	Definition of depression
Agustini et al	ACEI	2020	Australia, United States	OR	1.08 (0.95–1.23)	≥65	46.2	14,195	CES-D
Agustini <i>et al</i>	ARB	2020		OR	0.99 (0.89–1.12)		38.6		
Agustini <i>et al</i>	BB	2020		OR	1.37 (1.16–1.60)		30.8		
Agustini <i>et al</i>	CCB	2020		OR	1.05 (0.92–1.19)		42.2		
Boal <i>et al</i>	AA	2016	United Kingdom	OR	0.54 (0.30-0.97)	40-80	56	144,066	ICD-9 and ICD-10
Boal <i>et al</i>	BB	2016		OR	1.06 (0.70–1.60)		45.1		
Boal <i>et al</i>	CCB	2016		OR	1.17 (0.68–2.01)		48.5		
Boal <i>et al</i>	TZ	2016		OR	0.90 (0.42-1.90)		28.5		
Cao <i>et al</i>	ACEI	2019	China	RR	1.24 (1.18–1.31)	≥18	50.9	181,709	antidepressant prescription
Cao et al	BB	2019		RR	1.21 (1.16–1.26)		44.3		
Cao et al	CCB	2019		RR	1.10 (1.06–1.14)		47.3		
Cao <i>et al</i>	DIU	2019		RR	1.02 (0.94-1.09)		51.3		
Feng <i>et al</i>	ACEI	2008	Singapore	OR	1.11 (0.73–1.68)	≥55	NR	2,804	GDS
Feng et al	BB	2008		OR	0.90 (0.66–1.21)				
Feng et al	CCB	2008		OR	0.91 (0.65–1.29)				
Feng et al	DIU	2008		OR	1.07 (0.68–1.67)				
Gerstman <i>et al</i>	BB	1996	United States	RR	0.8 (0.3–1.9)	NR	38.3	3,782	DSM-III-R
Johansen <i>et al</i>	ACEI	2012	Norway	OR	0.54 (0.28-1.08)	≥20	NR	55,472	HADS
Johansen <i>et al</i>	BB	2012		OR	1.20 (0.78–1.83)				
Johansen <i>et al</i>	CCB	2012		OR	1.04 (0.70–1.53)				
Michal <i>el al</i>	BB	2013	Germany	OR	1.45 (1.06–1.98)	35–74	NR	5,000	PHQ-9
Michal et al	ACEI	2013		OR	1.23 (0.91–1.66)				
Michal et al	CCB	2013		OR	0.81 (0.49–1.33)				
Michal et al	DIU	2013		OR	1.09 (0.66–1.78)				
Ringoir <i>et al</i>	Lipophilic BB	2014	Netherlands	OR	1.60 (1.08–2.36)	60–85	43	573	PHQ-9
Simonson et al	BB	2010	United States	OR	0.76 (0.63–0.90)	NR	NR	7,272	ICD-9-CM

TABLE 1 | Characteristics of included studies.

ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CCB, calcium channel blockers; BB, beta blockers; DIU, diuretics; TZ, thiazide diuretics; AA, angiotensin antagonists; OR, odds ratio; CI, confidence interval; RR, relative risk; NR, not reported; CES-D, Center for Epidemiological Studies Depression; ICD, International Classification of Diseases; GDS, Geriatric Depression Scale; DSM, Diagnostic and Statistical Manual of Mental Disorders; HADS, Hospital Anxiety and Depression rating Scale; PHQ-9, Patient Health Questionnaire 9.

no significant associations with the incidence of depression or symptoms of depression (**Figures 2B–D**). The pooled ORs and 95% CI of depression were 1.09 (95% CI 0.96–1.25) for angiotensin antagonists, 1.18 (95% CI 0.99–1.41) for beta blockers and 1.03 (95% CI 0.95–1.10) for diuretics, respectively.

Heterogeneity and Publication Bias

Given the obvious heterogeneity shown in the forest plots, the sensitivity analysis was conducted by omitting one study at a time (**Supplementary Figure S1**). In line with the results earlier mentioned, associations between angiotensin antagonists and diuretics use and depression were little, and the result was not excessively influenced by any single study (**Supplementary Figures S1A,B**). After removing the study by Simonson *et al.*, a significant association between use of beta blockers and depression was observed (pooled OR: 1.26; 95% CI, 1.12–1.42) with the heterogeneity (I^2 value) decreasing from 85 to 40% (**Supplementary Figure S1C**). When the study by Cao *et al.* was excluded, no association was found between calcium channel blockers usage and depression (**Supplementary Figure S1D**).

To evaluate publication bias, funnel plots were constructed. No publication bias was found in the beta blockers group (**Supplementary Figure S2A**), while apparent biases were found in the other three groups (Supplementary Figures S2B-D).

Subgroup Analysis Type of Control Group

Given the heterogeneity of the controls, subgroup analysis was performed via dividing the controls into two subgroups, NoAntiHTN and AntiHTN, to investigate the impact of antihypertensive drugs use. The subgroup analysis of AntiHTN control group indicated use of antihypertensives increased risk of depression: angiotensin antagonists (OR 1.14, 95% CI 0.99–1.31), beta blockers (OR 1.18, 95% CI 0.99–1.41), and calcium channel blockers (OR 1.10, 95% CI 1.06–1.13) (**Figure 3**). However, the subgroup analysis of NoAntiHTN control group found no relationship between any class of antihypertensive drugs and risk of depression: angiotensin antagonists (OR 0.86, 95% CI 0.39–1.92), beta blockers (OR 1.20, 95% CI 0.83–1.76), and calcium channel blockers (OR 0.95, 95% CI 0.70–1.29) (**Figure 3**).

Type of Study

Subgroup analysis on the basis of study type (cohort/crosssectional) suggested that there was a significant connection for beta blockers (OR 1.21, 95% CI 1.16–1.26) usage in

A Author	PMID	Odds Ratio	OR	95% CI	Weight	-
			UR	95%CI	(iixed)	(random)
Agustini et al, 2020	32001828		1.05	[0.92; 1.19]	7.2%	22.7%
Cao et al, 2019	31470183	<u> </u>	1.10	[1.06; 1.14]	90.3%	66.9%
Boal et al, 2016	27733585		2.15	[0.99; 4.66]	0.2%	0.9%
Michal et al, 2013	23449018	<	0.81	[0.49; 1.33]	0.5%	2.0%
Johansen et al, 2012	22183137	<		[0.70; 1.54]		3.3%
Feng et al, 2008	18729549	<+ <u> </u>		[0.65; 1.28]		4.2%
Fixed effect model		•	1.09	[1.06; 1.13]	100.0%	
Random effects model				[1.00; 1.16]		100.0%
Heterogeneity: $I^2 = 16\%$, p	= 0.31	0.75 1 1.5 2.2		[]		
В					Mar	14 /- i - h
	DMID	Odda Datia	0.0	05% 01	Weight	
Author	PMID	Odds Ratio	OR	95%CI	(fixed)	(random
Agustini et al ^a , 2020	32001828	-	1.08	[0.95; 1.23]	11.5%	23.5%
Agustini et al ^b , 2020	32001828		0.99	[0.88; 1.11]	14.5%	24.6%
Cao et al ^a , 2019	31470183		1.24	[1.18; 1.31]	70.3%	28.8%
Michal et al ^a , 2013	23449018		1.23	[0.91; 1.66]	2.1%	11.9%
Johansen et al ^a , 2012	22183137	<		[0.27; 1.06]		3.5%
Feng et al ^c , 2008	18729549			[0.73; 1.68]		7.7%
Fixed effect model		\$	1.18	[1.12; 1.23]	100.0%	
Random effects model				[0.96; 1.25]		100.0%
Heterogeneity: $I^2 = 74\%$, p	0 < 0 01	0.5 0.75 1 1.5 1.7		,		
		0.5 0.75 1 1.5 1.7				
C					Weight	Weight
	PMID	Odds Ratio	OR	95%CI		
Author	PMID 32001828	Odds Ratio		95%Cl [1.17; 1.61]	(fixed)	(random)
Author Agustini et al, 2020		Odds Ratio	1.37		(fixed)	Weight (random) 15.7% 17.9%
Author Agustini et al, 2020 Cao et al, 2019	32001828	Odds Ratio	1.37 1.21	[1.17; 1.61]	(fixed) 5.2% 78.6%	(random) 15.7% 17.9%
Author Agustini et al, 2020 Cao et al, 2019 Boal et al, 2016	32001828 31470183	Odds Ratio	1.37 1.21 1.94	[1.17; 1.61] [1.16; 1.26] [0.98; 3.86]	(fixed) 5.2% 78.6% 0.3%	(random) 15.7% 17.9% 4.8%
Author Agustini et al, 2020 Cao et al, 2019 Boal et al, 2016 Ringoir et al, 2014	32001828 31470183 27733585 24911300	Odds Ratio	1.37 1.21 1.94 1.60	[1.17; 1.61] [1.16; 1.26] [0.98; 3.86] [1.08; 2.37]	(fixed) 5.2% 78.6% 0.3% 0.9%	(random) 15.7% 17.9% 4.8% 9.5%
Author Agustini et al, 2020 Cao et al, 2019 Boal et al, 2016 Ringoir et al, 2014 Michal et al, 2013	32001828 31470183 27733585 24911300 23449018	Odds Ratio	1.37 1.21 1.94 1.60 1.45	[1.17; 1.61] [1.16; 1.26] [0.98; 3.86] [1.08; 2.37] [1.06; 1.98]	(fixed) 5.2% 78.6% 0.3% 0.9% 1.4%	(random) 15.7% 17.9% 4.8% 9.5% 11.5%
Author Agustini et al, 2020 Cao et al, 2019 Boal et al, 2016 Ringoir et al, 2014 Michal et al, 2013 Johansen et al, 2012	32001828 31470183 27733585 24911300 23449018 22183137		1.37 1.21 1.94 1.60 1.45 1.20	[1.17; 1.61] [1.16; 1.26] [0.98; 3.86] [1.08; 2.37] [1.06; 1.98] [0.78; 1.84]	(fixed) 5.2% 78.6% 0.3% 0.9% 1.4% 0.7%	(random) 15.7% 17.9% 4.8% 9.5% 11.5% 8.8%
Author Agustini et al, 2020 Cao et al, 2019 Boal et al, 2016 Ringoir et al, 2014 Michal et al, 2013 Johansen et al, 2012 Simonson et al, 2010	32001828 31470183 27733585 24911300 23449018 22183137 21194659	Odds Ratio	1.37 1.21 1.94 1.60 1.45 1.20 0.83	[1.17; 1.61] [1.16; 1.26] [0.98; 3.86] [1.08; 2.37] [1.06; 1.98] [0.78; 1.84] [0.74; 0.93]	(fixed) 5.2% 78.6% 0.3% 0.9% 1.4% 0.7% 11.3%	(random) 15.7% 17.9% 4.8% 9.5% 11.5% 8.8% 16.9%
Author Agustini et al, 2020 Cao et al, 2019 Boal et al, 2016 Ringoir et al, 2014 Michal et al, 2013 Johansen et al, 2012 Simonson et al, 2010 Feng et al, 2008	32001828 31470183 27733585 24911300 23449018 22183137		1.37 1.21 1.94 1.60 1.45 1.20 0.83 0.90	[1.17; 1.61] [1.16; 1.26] [0.98; 3.86] [1.08; 2.37] [1.06; 1.98] [0.78; 1.84]	(fixed) 5.2% 78.6% 0.3% 0.9% 1.4% 0.7% 11.3% 1.5%	(random) 15.7% 17.9% 4.8% 9.5% 11.5% 8.8% 16.9% 11.8%
Author Agustini et al, 2020 Cao et al, 2019 Boal et al, 2016 Ringoir et al, 2014 Michal et al, 2013 Johansen et al, 2012 Simonson et al, 2010 Feng et al, 2008 Gerstman et al, 1996	32001828 31470183 27733585 24911300 23449018 22183137 21194659 18729549		1.37 1.21 1.94 1.60 1.45 1.20 0.83 0.90 0.80	[1.17; 1.61] [1.16; 1.26] [0.98; 3.86] [1.08; 2.37] [1.06; 1.98] [0.78; 1.84] [0.74; 0.93] [0.66; 1.22] [0.32; 2.01]	(fixed) 5.2% 78.6% 0.3% 0.9% 1.4% 0.7% 11.3% 1.5% 0.2%	(random) 15.7% 17.9% 4.8% 9.5% 11.5% 8.8% 16.9% 11.8%
Author Agustini et al, 2020 Cao et al, 2019 Boal et al, 2016 Ringoir et al, 2014 Michal et al, 2013 Johansen et al, 2012 Simonson et al, 2010 Feng et al, 2008 Gerstman et al, 1996	32001828 31470183 27733585 24911300 23449018 22183137 21194659 18729549		1.37 1.21 1.94 1.60 1.45 1.20 0.83 0.90 0.80 1.17	[1.17; 1.61] [1.16; 1.26] [0.98; 3.86] [1.08; 2.37] [1.06; 1.98] [0.78; 1.84] [0.74; 0.93] [0.66; 1.22] [0.32; 2.01] [1.13; 1.21]	(fixed) 5.2% 78.6% 0.3% 0.9% 1.4% 0.7% 11.3% 1.5% 0.2% 100.0%	(random) 15.7% 17.9% 4.8% 9.5% 11.5% 8.8% 16.9% 11.8% 3.0%
Author Agustini et al, 2020 Cao et al, 2019 Boal et al, 2016 Ringoir et al, 2014 Michal et al, 2013 Johansen et al, 2013 Simonson et al, 2010 Feng et al, 2008 Gerstman et al, 1996 Fixed effect model Random effects model	32001828 31470183 27733585 24911300 23449018 22183137 21194659 18729549 8691233		1.37 1.21 1.94 1.60 1.45 1.20 0.83 0.90 0.80 1.17	[1.17; 1.61] [1.16; 1.26] [0.98; 3.86] [1.08; 2.37] [1.06; 1.98] [0.78; 1.84] [0.74; 0.93] [0.66; 1.22] [0.32; 2.01]	(fixed) 5.2% 78.6% 0.3% 0.9% 1.4% 0.7% 11.3% 1.5% 0.2% 100.0%	(random)
C Author Agustini et al, 2020 Cao et al, 2019 Boal et al, 2016 Ringoir et al, 2014 Michal et al, 2013 Johansen et al, 2013 Johansen et al, 2010 Feng et al, 2008 Gerstman et al, 1996 Fixed effect model Random effects model Heterogeneity: I ² = 85%, p	32001828 31470183 27733585 24911300 23449018 22183137 21194659 18729549 8691233		1.37 1.21 1.94 1.60 1.45 1.20 0.83 0.90 0.80 1.17	[1.17; 1.61] [1.16; 1.26] [0.98; 3.86] [1.08; 2.37] [1.06; 1.98] [0.78; 1.84] [0.74; 0.93] [0.66; 1.22] [0.32; 2.01] [1.13; 1.21]	(fixed) 5.2% 78.6% 0.3% 0.9% 1.4% 0.7% 11.3% 1.5% 0.2% 100.0%	(random) 15.7% 17.9% 4.8% 9.5% 11.5% 8.8% 16.9% 11.8% 3.0%
Author Agustini et al, 2020 Cao et al, 2019 Boal et al, 2016 Ringoir et al, 2014 Michal et al, 2013 Johansen et al, 2013 Simonson et al, 2010 Feng et al, 2008 Gerstman et al, 1996 Fixed effect model Random effects model	32001828 31470183 27733585 24911300 23449018 22183137 21194659 18729549 8691233		1.37 1.21 1.94 1.60 1.45 1.20 0.83 0.90 0.80 1.17	[1.17; 1.61] [1.16; 1.26] [0.98; 3.86] [1.08; 2.37] [1.06; 1.98] [0.78; 1.84] [0.74; 0.93] [0.66; 1.22] [0.32; 2.01] [1.13; 1.21]	(fixed) 5.2% 78.6% 0.3% 0.9% 1.4% 0.7% 11.3% 1.5% 0.2% 100.0%	(random) 15.7% 17.9% 4.8% 9.5% 11.5% 8.8% 16.9% 11.8% 3.0%
Author Agustini et al, 2020 Cao et al, 2019 Boal et al, 2016 Ringoir et al, 2014 Michal et al, 2013 Johansen et al, 2012 Simonson et al, 2010 Feng et al, 2008 Gerstman et al, 1996 Fixed effect model Random effects model Heterogeneity: I ² = 85%, p	32001828 31470183 27733585 24911300 23449018 22183137 21194659 18729549 8691233		1.37 1.21 1.94 1.60 1.45 1.20 0.83 0.90 0.80 1.17	[1.17; 1.61] [1.16; 1.26] [0.98; 3.86] [1.08; 2.37] [1.06; 1.98] [0.78; 1.84] [0.74; 0.93] [0.66; 1.22] [0.32; 2.01] [1.13; 1.21]	(fixed) 5.2% 78.6% 0.3% 0.9% 1.4% 0.7% 11.3% 1.5% 0.2% 100.0% 	(random) 15.7% 17.9% 4.8% 9.5% 11.5% 8.8% 16.9% 11.8% 3.0%
Author Agustini et al, 2020 Cao et al, 2019 Boal et al, 2016 Ringoir et al, 2014 Michal et al, 2013 Johansen et al, 2012 Simonson et al, 2010 Feng et al, 2008 Gerstman et al, 1996 Fixed effect model Random effects model Heterogeneity: I ² = 85%, p	32001828 31470183 27733585 24911300 23449018 22183137 21194659 18729549 8691233		1.37 1.21 1.94 1.60 1.45 1.20 0.83 0.90 0.80 1.17 1.18	[1.17; 1.61] [1.16; 1.26] [0.98; 3.86] [1.08; 2.37] [1.06; 1.98] [0.78; 1.84] [0.74; 0.93] [0.66; 1.22] [0.32; 2.01] [1.13; 1.21] [0.99; 1.41]	(fixed) 5.2% 78.6% 0.3% 0.9% 1.4% 0.7% 11.3% 1.5% 0.2% 100.0% Weight (fixed)	(random 15.7% 17.9% 4.8% 9.5% 11.5% 8.8% 16.9% 11.8% 3.0% 100.0% Weight (random
Author Agustini et al, 2020 Cao et al, 2019 Boal et al, 2016 Ringoir et al, 2014 Michal et al, 2013 Johansen et al, 2013 Johansen et al, 2012 Simonson et al, 2010 Feng et al, 2008 Gerstman et al, 1996 Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 85%, <i>p</i> D Author Cao et al, 2019	32001828 31470183 27733585 24911300 23449018 22183137 21194659 18729549 8691233 0<0.01		1.37 1.21 1.94 1.60 1.45 1.20 0.83 0.90 0.80 1.17 1.18 OR 1.02	[1.17; 1.61] [1.16; 1.26] [0.98; 3.86] [1.08; 2.37] [1.06; 1.98] [0.78; 1.84] [0.74; 0.93] [0.66; 1.22] [0.32; 2.01] [1.13; 1.21] [0.99; 1.41]	(fixed) 5.2% 78.6% 0.3% 0.9% 1.4% 0.7% 11.3% 1.5% 0.2% 100.0% Weight (fixed) 94.7%	(random 15.7% 17.9% 4.8% 9.5% 11.5% 8.8% 16.9% 11.8% 3.0% 100.0% Weigh (random 94.7%
Author Agustini et al, 2020 Cao et al, 2019 Boal et al, 2016 Ringoir et al, 2016 Michal et al, 2013 Johansen et al, 2012 Simonson et al, 2010 Feng et al, 2008 Gerstman et al, 1996 Fixed effect model Random effects model Heterogeneity: I ² = 85%, p D Author Cao et al, 2019 Boal et al, 2016	32001828 31470183 27733585 24911300 23449018 22183137 21194659 18729549 8691233 0 < 0.01		1.37 1.21 1.94 1.60 1.45 1.20 0.83 0.90 0.80 1.17 1.18 OR 1.02 1.65	[1.17; 1.61] [1.16; 1.26] [0.98; 3.86] [1.08; 2.37] [1.06; 1.98] [0.78; 1.84] [0.74; 0.93] [0.66; 1.22] [0.32; 2.01] [1.13; 1.21] [0.99; 1.41] 95%CI [0.95; 1.10] [0.65; 4.19]	(fixed) 5.2% 78.6% 0.3% 0.9% 1.4% 0.7% 11.3% 1.5% 0.2% 100.0% Weight (fixed) 94.7% 0.6%	(random) 15.7% 17.9% 4.8% 9.5% 11.5% 8.8% 16.9% 11.8% 3.0% 100.0% Weight (random) 94.7% 0.6%
Author Agustini et al, 2020 Cao et al, 2019 Boal et al, 2016 Ringoir et al, 2014 Michal et al, 2013 Johansen et al, 2013 Johansen et al, 2012 Simonson et al, 2010 Feng et al, 2008 Gerstman et al, 1996 Fixed effect model Random effects model Heterogeneity: <i>I</i> ² = 85%, <i>p</i> D Author Cao et al, 2019	32001828 31470183 27733585 24911300 23449018 22183137 21194659 18729549 8691233 0<0.01		1.37 1.21 1.94 1.60 1.45 1.20 0.83 0.90 0.80 1.17 1.18 OR 1.02 1.65 1.09	[1.17; 1.61] [1.16; 1.26] [0.98; 3.86] [1.08; 2.37] [1.06; 1.98] [0.78; 1.84] [0.74; 0.93] [0.66; 1.22] [0.32; 2.01] [1.13; 1.21] [0.99; 1.41]	(fixed) 5.2% 78.6% 0.3% 0.9% 1.4% 0.7% 1.5% 0.2% 100.0% Weight (fixed) 94.7% 0.6% 2.1%	(random 15.7% 17.9% 4.8% 9.5% 11.5% 8.8% 16.9% 11.8% 3.0% 100.0% Weight (random 94.7% 0.6% 2.1%
Author Agustini et al, 2020 Cao et al, 2019 Boal et al, 2016 Ringoir et al, 2014 Michal et al, 2013 Johansen et al, 2013 Johansen et al, 2010 Feng et al, 2008 Gerstman et al, 1996 Fixed effect model Random effects model Heterogeneity: $I^2 = 85\%$, p D Author Cao et al, 2019 Boal et al, 2016 Michal et al, 2013 Feng et al, 2008	32001828 31470183 27733585 24911300 23449018 22183137 21194659 18729549 8691233 • < 0.01 • • • • • • • • • • • • • • • • • • •		1.37 1.21 1.94 1.60 1.45 1.20 0.83 0.90 0.80 1.17 1.18 OR 1.02 1.65 1.09 1.07	[1.17; 1.61] [1.16; 1.26] [0.98; 3.86] [1.08; 2.37] [1.06; 1.98] [0.78; 1.84] [0.74; 0.93] [0.66; 1.22] [0.32; 2.01] [1.13; 1.21] [0.99; 1.41] 95%CI [0.95; 1.10] [0.65; 4.19] [0.66; 1.79] [0.68; 1.68]	(fixed) 5.2% 78.6% 0.3% 0.9% 1.4% 0.7% 11.3% 1.5% 0.2% 100.0% Weight (fixed) 94.7% 0.6% 2.1% 2.6%	(random 15.7% 17.9% 4.8% 9.5% 11.5% 8.8% 16.9% 11.8% 3.0% 100.0% Weight (random 94.7% 0.6% 2.1%
Author Agustini et al, 2020 Cao et al, 2019 Boal et al, 2016 Ringoir et al, 2013 Johansen et al, 2013 Johansen et al, 2010 Feng et al, 2008 Gerstman et al, 1996 Fixed effect model Random effects model Heterogeneity: I ² = 85%, p D Author Cao et al, 2019 Boal et al, 2016 Michal et al, 2013	32001828 31470183 27733585 24911300 23449018 22183137 21194659 18729549 8691233 • < 0.01 • • • • • • • • • • • • • • • • • • •		1.37 1.21 1.94 1.60 1.45 1.20 0.83 0.90 0.80 1.17 1.18 OR 1.02 1.65 1.09 1.07	[1.17; 1.61] [1.16; 1.26] [0.98; 3.86] [1.08; 2.37] [1.06; 1.98] [0.78; 1.84] [0.74; 0.93] [0.66; 1.22] [0.32; 2.01] [1.13; 1.21] [0.99; 1.41] 95%CI [0.95; 1.10] [0.65; 4.19] [0.66; 1.79]	(fixed) 5.2% 78.6% 0.3% 0.9% 1.4% 0.7% 11.3% 1.5% 0.2% 100.0% Weight (fixed) 94.7% 0.6% 2.1% 2.6%	(random) 15.7% 17.9% 4.8% 9.5% 11.5% 8.8% 16.9% 11.8% 3.0%

FIGURE 2 | Forest plots for different classes of antihypertensives and risk of depression. (A) Calcium channel blockers group. (B) Angiotensin antagonists group. (C) Beta blockers group. (D) Diuretics group. ^(a-c) indicate angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and angiotensin antagonists, respectively.

Α					Weight	-
Author	PMID	Odds Ratio	OR	95%CI	(fixed)	(random
AntiHTN						
Feng et al ^c , 2008	18729549			[0.99; 2.10]		
Cao et al ^a , 2019	31470183	-	1.24	[1.18; 1.31]	70.1%	28.1%
Agustini et al ^a , 2020	32001828	-		[0.95; 1.23]		
Agustini et al ^b , 2020	32001828	-		[0.88; 1.11]		
Fixed effect model		*		[1.13; 1.24]	97.5%	
Random effects mode Heterogeneity: I ² = 80%,		\$	1.14	[0.99; 1.31]		84.4%
NoAntiHTN						
Johansen et al, 2012	22183137		0.54	[0.27; 1.06]	0.4%	3.6%
Michal et al, 2013	23449018			[0.91; 1.66]		
Fixed effect model	20110010			[0.82; 1.41]		
Random effects mode	i.			[0.39; 1.92]		15.6%
Heterogeneity: $I^2 = 79\%$,			0.00	[0.00, 1.02]		15.078
Fixed effect model		\$		[1.13; 1.23]		
Random effects mode			1.12	[0.98; 1.28]		100.0%
Heterogeneity: / ² = 76%, Residual heterogeneity: /						
В					Weight	Weight
Author	PMID	Odds Ratio	OR	95%CI		(random)
AntiHTN		1				
	0004000		0.00	10 00. 0 041	0.00/	0.40/
Gerstman et al, 1996	8691233			[0.32; 2.01]		3.1%
Feng et al, 2008	18729549			[0.60; 1.10]	1.5%	11.8%
Boal et al, 2016	27733585			[0.98; 3.86]	0.3%	4.9%
Cao et al, 2019	31470183			[1.16; 1.26]	78.6%	17.7%
Agustini et al, 2020	32001828			[1.17; 1.61]	5.2%	15.6%
Fixed effect model		•		[1.16; 1.26]	85.7%	
Random effects mode			1.18	[0.99; 1.41]		53.1%
Heterogeneity: / ² = 66%,	ρ = 0.02					
NoAntiHTN	01404050	-	0.00	10 74 0 001	44.00/	40 70/
Simonson et al, 2010	21194659			[0.74; 0.93]		16.7%
Johansen et al, 2012	22183137			[0.78; 1.84]		8.9%
Michal et al, 2013	23449018			[1.06; 1.98]	1.4%	11.6%
Ringoir et al, 2014	24911300			[1.08; 2.37]	0.9%	9.7%
Fixed effect model	,			[0.84; 1.02]		
Random effects mode Heterogeneity: 1 ² = 86%,			1.20	[0.83; 1.76]		46.9%
					- 1977-1977 - 1977-19	
Fixed effect model Random effects mode	J	*		[1.12; 1.21] [0.98; 1.40]		 100.0%
Heterogeneity: $I^2 = 86\%$,	0.04	75 1 1.5 2.1		[0.50, 1.40]		100.078
Residual heterogeneity: /						
C	-		~ ~	050/01	-	Weight
Author	PMID	Odds Ratio	OR	95%CI	(fixed)	(random)
AntiHTN Feng et al, 2008	18729549		0.07	10 70- 1 261	1.1%	2.7%
•		3		[0.70; 1.35]		
Boal et al, 2016	27733585	;		[0.99; 4.66]	0.2%	0.5%
Cao et al, 2019	31470183	3		[1.06; 1.14]		78.0%
Agustini et al, 2020	32001828			[0.92; 1.19]		15.7%
Fixed effect model Random effects mode	J			[1.06; 1.13] [1.01; 1.17]		96.9%
Heterogeneity: $I^2 = 23\%$,			1.09	[1.01, 1.17]		90.9%
		5 5 7 3 5				
NoAntiHTN	00100107	3	1.04	10 70: 4 5 4	0.00/	4.08/
Johansen et al, 2012	22183137			[0.70; 1.54]		1.9%
Michal at al. 2012	23449018			[0.49; 1.33]		1.2%
				[0.70; 1.29] [0.70; 1.29]		
Fixed effect model						3.1%
Fixed effect model Random effects mode			0.95	[0.70, 1.25]		
Michal et al, 2013 Fixed effect model Random effects mode Heterogeneity: / ² = 0%, p						
Fixed effect model Random effects mode	0 = 0.44		1.09	[1.06; 1.13] [1.03; 1.15]	100.0%	 100.0%

FIGURE 3 | Forest plots of subgroup analysis according to the type of control group (NoAntiHTN/AntiHTN) in (A) angiotensin antagonists, (B) beta blockers and (C) calcium channel blockers group. ^(a-c) indicate angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and angiotensin antagonists, respectively.

cohort studies and no significant connection between drug use and the risk of depression in cross-sectional studies (Figure 4).

							Weight	Weight
Author	PMID		Odds Ratio		OR	95%CI		(random
cross-sectional			1					
Agustini et al, 2020	32001828				1.37	[1.17; 1.61]	5.2%	15.79
Feng et al, 2008	18729549					[0.66; 1.22]	1.5%	11.89
Johansen et al, 2012	22183137		1			[0.78; 1.84]		8.8%
Michal et al, 2013	23449018						1.4%	11.5%
			-	-		[1.06; 1.98]		
Ringoir et al, 2014	24911300	_		→		[1.08; 2.37]	0.9%	9.5%
Simonson et al, 2010	21194659	←				[0.74; 0.93]	11.3%	16.9%
Fixed effect model			~			[0.94; 1.11]		
Random effects mode			6		1.17	[0.90; 1.52]		74.2%
Heterogeneity: $I^2 = 87\%$,	p < 0.01							
cohort								
Boal et al, 2016	27733585			→	1.94	[0.98; 3.86]	0.3%	4.8%
Cao et al, 2019	31470183				1.21	[1.16; 1.26]	78.6%	17.9%
Gerstman et al, 1996	8691233	~		-	0.80	[0.32; 2.01]	0.2%	3.0%
Fixed effect model			0			[1.16; 1.26]		
Random effects mode	r.					[0.95; 1.63]		25.8%
Heterogeneity: 1 ² = 23%,					1.20	[0.95, 1.05]		25.07
					4 47	14 42. 4 241	400.0%	
Fixed effect model Random effects mode	1		-			[1.13; 1.21] [0.99; 1.41]		100.0%
Heterogeneity: / ² = 85%,	p < 0.01	0.75	1 1.5	2.1				
3							Weight	Weight
Author	PMID		Odds Ratio		OR	95%CI	(fixed) (-
ross-sectional			3					
gustini et al, 2020	32001828				1.05	[0.92; 1.19]	7.2%	22.79
eng et al, 2008	18729549					[0.65; 1.28]	1.0%	4.29
ohansen et al, 2012	22183137		19			[0.70; 1.54]	0.8%	3.39
Aichal et al, 2013	23449018	~ +	2			[0.49; 1.33]	0.5%	2.0%
ixed effect model			\$		1.02	[0.91; 1.14]	9.5%	
Random effects model			\$		1.02	[0.91; 1.14]		32.2%
Heterogeneity: $I^2 = 0\%$, p	= 0.69		2					
cohort			2					
Boal et al, 2016	27733585			→	2.15	[0.99; 4.66]	0.2%	0.9%
Cao et al, 2019	31470183		+			[1.06; 1.14]	90.3%	66.9%
ixed effect model	01110100		ف			[1.06; 1.14]	90.5%	
			Y				90.5%	
Random effects model leterogeneity: 1 ² = 65%,					1.37	[0.74; 2.54]		67.8%
			2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2					
Fixed effect model			•			[1.06; 1.13]	100.0%	
Random effects model Heterogeneity: / ² = 16%,			♦	7	1.08	[1.00; 1.16]		100.0%
leterogeneity. 7 = 10%,	<i>p</i> = 0.51	0.6 0.75	1 1.5	2.85				
-							Weiaht	Weight
C	DMID		Odda Patia					
author	PMID		Odds Ratio		OR	95%CI	(fixed) (random)
Author	PMID 27733585	.	Odds Ratio	→				
Author cohort Boal et al, 2016			Odds Ratio	→	1.65	95%CI [0.65; 4.19]	(fixed) (0.6%
Author sohort Boal et al, 2016 Cao et al, 2019	27733585		Odds Ratio	→	1.65 1.02	95%Cl [0.65; 4.19] [0.95; 1.10]	(fixed) (0.6% 94.7%	0.6%
Author sohort Boal et al, 2016 Cao et al, 2019 Fixed effect model	27733585 31470183		Odds Ratio	→	1.65 1.02 1.02	95%Cl [0.65; 4.19] [0.95; 1.10] [0.95; 1.10]	(fixed) (0.6% 94.7%
Author sohort Boal et al, 2016 Cao et al, 2019 Fixed effect model Random effects model	27733585 31470183		Odds Ratio	→	1.65 1.02 1.02	95%Cl [0.65; 4.19] [0.95; 1.10]	(fixed) (0.6% 94.7%	0.6% 94.7%
Author sohort Boal et al, 2016 Cao et al, 2019 Fixed effect model Random effects model	27733585 31470183		Odds Ratio	→	1.65 1.02 1.02	95%Cl [0.65; 4.19] [0.95; 1.10] [0.95; 1.10]	(fixed) (0.6% 94.7%	0.6% 94.7%
Author Joshort Soal et al, 2016 Soa et al, 2019 Fixed effect model Random effects model leterogeneity: <i>I</i> ² = 2%, <i>p</i>	27733585 31470183 = 0.31		Odds Ratio	→	1.65 1.02 1.02 1.03	95%Cl [0.65; 4.19] [0.95; 1.10] [0.95; 1.10] [0.92; 1.15]	(fixed) (0.6% 94.7% 95.3% 	0.6% 94.7% 95.3%
uthor ohort Coal et al, 2016 Cao et al, 2019 iixed effect model latndom effects model leterogeneity: /² = 2%, p ross-sectional lichal et al, 2013	27733585 31470183 = 0.31 23449018	<	Odds Ratio	→ -	1.65 1.02 1.02 1.03	95%Cl [0.65; 4.19] [0.95; 1.10] [0.95; 1.10] [0.92; 1.15] [0.66; 1.79]	(fixed) (0.6% 94.7% 95.3% 2.1%	0.6% 94.7% 95.3% 2.1%
Author solhort Soal et al, 2016 Cao et al, 2019 Fixed effect model Random effects model leterogeneity: I ² = 2%, p pross-sectional dichal et al, 2013	27733585 31470183 = 0.31	←	Odds Ratio	→ -	1.65 1.02 1.02 1.03	95%Cl [0.65; 4.19] [0.95; 1.10] [0.95; 1.10] [0.92; 1.15]	(fixed) (0.6% 94.7% 95.3% 	0.6% 94.7% 95.3% 2.1%
Author cohort 30al et al, 2016 2ao et al, 2019 Fixed effect model Random effects model Autore and Autore and Autore percess-sectional Michal et al, 2013 Feng et al, 2008	27733585 31470183 = 0.31 23449018			→ I	1.65 1.02 1.02 1.03 1.09 1.07	95%Cl [0.65; 4.19] [0.95; 1.10] [0.95; 1.10] [0.92; 1.15] [0.66; 1.79]	(fixed) (0.6% 94.7% 95.3% 2.1% 2.6%	0.69 94.79 95.3% 2.19 2.69
uthor Johort Soal et al, 2016 Sao et al, 2019 Vixed effect model Random effects model leterogeneity: I ² = 2%, p vross-sectional Alichal et al, 2013 Feng et al, 2008 Fixed effect model	27733585 31470183 = 0.31 23449018 18729549	Ĵ	•	→ -	1.65 1.02 1.02 1.03 1.03	95%CI [0.65; 4.19] [0.95; 1.10] [0.95; 1.10] [0.92; 1.15] [0.66; 1.79] [0.68; 1.68]	(fixed) (0.6% 94.7% 95.3% 2.1% 2.6%	0.69 94.79 95.3% 2.19 2.69
Author Solo at al, 2016 Solo at al, 2019 Fixed effect model Random effects model Heterogeneity: I ² = 2%, p pross-sectional Michal et al, 2013 Freng et al, 2008 Fixed effect model Random effects model Heterogeneity: I ² = 0%, p	27733585 31470183 = 0.31 23449018 18729549			→ -	1.65 1.02 1.02 1.03 1.03	95%Cl [0.65; 4.19] [0.95; 1.10] [0.95; 1.10] [0.92; 1.15] [0.66; 1.79] [0.68; 1.68] [0.77; 1.51]	(fixed) (0.6% 94.7% 95.3% 2.1% 2.6% 4.7%	0.69 94.79 95.3% 2.19 2.69
Solhort Solal et al, 2016 Soal et al, 2019 Fixed effect model Random effects model leterogeneity: <i>I</i> ² = 2%, <i>p</i> pross-sectional dichal et al, 2013 Freng et al, 2008 Random effects model	27733585 31470183 = 0.31 23449018 18729549	Ĵ		→	1.65 1.02 1.02 1.03 1.09 1.07 1.08 1.08	95%Cl [0.65; 4.19] [0.95; 1.10] [0.95; 1.10] [0.92; 1.15] [0.66; 1.79] [0.68; 1.68] [0.77; 1.51] [0.77; 1.51]	(fixed) (0.6% 94.7% 95.3% 2.1% 2.6% 4.7% 	0.69 94.79 95.3% 2.19 2.69
Solort Solor	27733585 31470183 = 0.31 23449018 18729549 = 0.96			-	1.65 1.02 1.02 1.03 1.09 1.07 1.08 1.08	95%Cl [0.65; 4.19] [0.95; 1.10] [0.95; 1.10] [0.92; 1.15] [0.66; 1.79] [0.66; 1.68] [0.77; 1.51] [0.77; 1.51]	(fixed) (0.6% 94.7% 95.3% 2.1% 2.6% 4.7% 100.0%	0.6% 94.7% 95.3% 2.1% 2.6%
Author cohort 30al et al, 2016 2ao et al, 2019 Fixed effect model Random effects model Heterogeneity: $I^2 = 2\%$, p pross-sectional Michal et al, 2013 Feng et al, 2008 Fixed effect model Random effects model Heterogeneity: $I^2 = 0\%$, p	27733585 31470183 = 0.31 23449018 18729549 = 0.96	0.7		→ - 1.85	1.65 1.02 1.02 1.03 1.09 1.07 1.08 1.08	95%Cl [0.65; 4.19] [0.95; 1.10] [0.95; 1.10] [0.92; 1.15] [0.66; 1.79] [0.68; 1.68] [0.77; 1.51] [0.77; 1.51]	(fixed) (0.6% 94.7% 95.3% 2.1% 2.6% 4.7% 100.0%	0.69 94.79 95.3% 2.19 2.69

FIGURE 4 | Forest plots of subgroup analysis according to the type of study (cohort/cross-sectional): (A) Beta blockers group. (B) Calcium channel blockers group. (C) Diuretics group.



Network Meta-analysis

A total of five studies, involving 263,025 participants, were included in the network meta-analysis. The network plot depicts the direct comparison between the treatment groups (Supplementary Figure S3). With reference to diuretics, except for the NoAntiHTN group, all antihypertensive treatments were significantly associated with higher risk of depression: beta blockers (OR 1.53, 95% CI 1.22-1.91), calcium channel blockers (OR 1.40, 95% CI 1.12-1.75) and angiotensin antagonists (OR 1.30, 95% CI 1.04-1.63) (Figure 5). Using NoAntiHTN group as comparison group, the odds ratios of network meta-analysis results were as follows: beta blockers 1.25 (95% CI 0.96-1.61), calcium channel blockers 1.14 (95% CI 0.88-1.48), angiotensin antagonists 1.06 (95% CI 0.81-1.39) and diuretics 0.82 (95% CI 0.60–1.11) (Supplementary Figure S4). The ranking P-score based on network meta-analysis was 0.056 for beta blockers, 0.305 for calcium channel blockers, 0.529 for angiotensin antagonists, 0.638 for NoAntiHTN, and 0.972 for diuretics (Supplementary Table S2).

There was moderate heterogeneity in the whole network metaanalysis (p = 0.011), and the between-designs Q statistic supported global consistency (p = 0.614). Local inconsistency in network meta-analysis is shown in **Supplementary Table S3** and **Supplementary Figure S5**. The comparison-adjusted funnel plot analysis demonstrated no publication bias (**Supplementary Figure S6**). Taken together, these results demonstrate the reliability of the net meta-analysis.

DISCUSSION

To clarify the role of antihypertensives use in depression, we conducted a systematic review and network meta-analysis. Compared with diuretics, our network meta-analysis results suggested that beta blockers, calcium channel blockers or angiotensin antagonists usage promote depression.

The network meta-analysis does not prespecify the standard, and it only compares multiple treatments simultaneously in a single analysis. Hence, the OR and 95% CI were different when the reference was changed to NoAntiHTN, while the rank order remained constant. However, there were no significant differences among all comparisons versus NoAntiHTN, which may be due to the small sample sizes and low statistical power of the studies than that comparisons versus diuretics.

The results of our traditional meta-analyses and subgroup analysis indicated that only the calcium channel blockers and beta blockers may increase the risk of depression. The network meta-analysis overcomes the limitation in conventional metaanalysis, because it can compare multiple antihypertensive treatments at the same time, rather than being restricted to comparisons of one drug class versus all others (Elliott and Meyer, 2007). The effect of the angiotensin antagonists on depression, therefore, may have been underestimated. In addition, although traditional meta-analysis indicated that calcium channel blockers use was associated with increased risk of depression, it is worth noting that this conclusion to a large extent was dependent on the cohort study by Cao et al. Due to its large sample size and relatively long follow-up duration, this study accounted for 90% weight of the fixed effect model (Cao et al., 2019). This study may confound the association between depression and antihypertensives use. To clarify the elusive link between depression and antihypertensive medicine, larger sample-sized cohort studies are warranted. Notably, in subgroup meta-analysis, we found different results in cross-sectional and cohort studies, and cohort studies have advantages over crosssectional studies. Differences between them may be related to study design, sample size, and duration of follow-up. The cross-sectional studies measure exposure and outcome simultaneously (Belbasis and Bellou, 2018), thus, only association can be established. As for cohort studies, as stated by Belbasis et al., "a cohort study tracks two or more groups forward from exposure to outcome" (Belbasis and Bellou, 2018). Cohort studies have a clear temporality in support of causal inference. In our meta-analysis, number of included cohort studies was relatively small, so more articles with cohort design would be necessary to further verify our results.

Currently, most studies suggest that beta blockers usage is accompanied by increased susceptibility to depression. However, Simonson et al. reported a converse association between them. This study points out that the fact that the various findings are difficult to explain because of the diverse etiologies of the cardiovascular conditions (Simonson et al., 2011). Jeon et al. also found bidirectional association between blood pressure and symptoms of depression, in a large cohort study of young and middle-aged individuals (Jeon et al., 2020). A recent meta-analysis (Riemer et al., 2021) which investigated the risk of psychiatric adverse events during beta blockers therapy found no association between beta blockers use and depression, while the majority of beta blocker trials were conducted almost 20 years ago. The controversy regarding beta blockers use and depression may be explained by the heterogeneity of populations (Agustini et al., 2020). In the studies which found a positive or no association of beta blockers with symptoms of depression, the

participants with a history of cardiovascular diseases, myocardial infarction or heart failure and distinct age groups were often included (Gerstman et al., 1996; Johansen et al., 2012), hence, the impact of beta blockers on general health improvement may outweigh or confound its effect on mood. It is therefore recommended that rigorous inclusion and exclusion criteria should be instituted in future studies focusing on the role of beta blockers in depression.

There are several limitations of this study that should be noted. First, there were moderate heterogeneity in network metaanalysis and considerable heterogeneity between studies in meta-analysis, even in the subgroup meta-analysis, which may influence the reliability of results. But, this is an inevitable problem. The type of study (cohort/cross-sectional) and measure of depression are both potential sources of heterogeneity. Indeed, there may be other unknown sources of heterogeneity. Therefore, the random-effects model was used to complete the network meta-analysis, which conservatively accounts for heterogeneity. Second, depression is approximately twice as prevalent in women as it is in men (Van de Velde et al., 2010). Yet much of the data from the studies we used were not stratified by gender. This prevented us from further assessing the differences between gender and risk of depression.

In conclusion, the outcome of this network meta-analysis supports the view that beta blockers, calcium channel blockers or angiotensin antagonists usage may be risk factors of depression. Our findings may be helpful in the management of depression by hypertensive individuals.

REFERENCES

- Agustini, B., Mohebbi, M., Woods, R. L., McNeil, J. J., Nelson, M. R., Shah, R. C., et al. (2020). The Association of Antihypertensive Use and Depressive Symptoms in a Large Older Population with Hypertension Living in Australia and the United States: a Cross-Sectional Study. J. Hum. Hypertens. 34 (11), 787–794. doi:10.1038/s41371-020-0303-y
- Belbasis, L., and Bellou, V. (2018). Introduction to Epidemiological Studies. Methods Mol. Biol. 1793, 1–6. doi:10.1007/978-1-4939-7868-7_1
- Beurel, E., Toups, M., and Nemeroff, C. B. (2020). The Bidirectional Relationship of Depression and Inflammation: Double Trouble. *Neuron* 107 (2), 234–256. doi:10.1016/j.neuron.2020.06.002
- Boal, A. H., Smith, D. J., McCallum, L., Muir, S., Touyz, R. M., Dominiczak, A. F., et al. (2016). Monotherapy with Major Antihypertensive Drug Classes and Risk of Hospital Admissions for Mood Disorders. *Hypertension* 68 (5), 1132–1138. doi:10.1161/HYPERTENSIONAHA.116.08188
- Cao, Y. Y., Xiang, X., Song, J., Tian, Y. H., Wang, M. Y., Wang, X. W., et al. (2019).
 Distinct Effects of Antihypertensives on Depression in the Real-World Setting:
 A Retrospective Cohort Study. J. Affect Disord. 259, 386–391. doi:10.1016/ j.jad.2019.08.075
- Cathomas, F., Murrough, J. W., Nestler, E. J., Han, M. H., and Russo, S. J. (2019). Neurobiology of Resilience: Interface between Mind and Body. *Biol. Psychiatry* 86 (6), 410–420. doi:10.1016/j.biopsych.2019.04.011
- Cruickshank, J. M. (2017). The Role of Beta-Blockers in the Treatment of Hypertension. Adv. Exp. Med. Biol. 956, 149–166. doi:10.1007/5584_2016_36
- Elliott, W. J., and Meyer, P. M. (2007). Incident Diabetes in Clinical Trials of Antihypertensive Drugs: a Network Meta-Analysis. *Lancet* 369 (9557), 201–207. doi:10.1016/S0140-6736(07)60108-1
- Feng, L., Tan, C. H., Merchant, R. A., and Ng, T. P. (2008). Association between Depressive Symptoms and Use of HMG-CoA Reductase

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/**Supplementary Material**, further inquiries can be directed to the corresponding authors.

AUTHOR CONTRIBUTIONS

GM and PX conceived the study. YS and YL selected of relevant literature and extracted the relevant data. YL analyzed and interpreted the data. YL and YF wrote the first draft of the manuscript. GM and RNA reviewed and revised the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was partially supported by the National Natural Science Foundation of China (Grant No. 81903390) and the Natural Science Foundation of Jiangsu Province (Grant Nos. BK20190555, BK20190600).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.777987/full#supplementary-material

Inhibitors (Statins), Corticosteroids and Histamine H(2) Receptor Antagonists in Community-Dwelling Older Persons: Cross-Sectional Analysis of a Population-Based Cohort. *Drugs Aging* 25 (9), 795–805. doi:10.2165/00002512-200825090-00005

- Foster, J. A., and McVey Neufeld, K. A. (2013). Gut-brain axis: How the Microbiome Influences Anxiety and Depression. *Trends Neurosci.* 36 (5), 305–312. doi:10.1016/j.tins.2013.01.005
- Gerstman, B. B., Jolson, H. M., Bauer, M., Cho, P., Livingston, J. M., and Platt, R. (1996). The Incidence of Depression in New Users of Beta-Blockers and Selected Antihypertensives. J. Clin. Epidemiol. 49 (7), 809–815. doi:10.1016/ 0895-4356(96)00017-0
- Higgins, J. P., Thompson, S. G., Deeks, J. J., and Altman, D. G. (2003). Measuring Inconsistency in Meta-Analyses. *BMJ* 327 (7414), 557–560. doi:10.1136/ bmj.327.7414.557
- James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., et al. (20142014). 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA 311 (5), 507–520. doi:10.1001/jama.2013.284427
- Jeon, S. W., Chang, Y., Lim, S. W., Cho, J., Kim, H. N., Kim, K. B., et al. (2020). Bidirectional Association between Blood Pressure and Depressive Symptoms in Young and Middle-Age Adults: A Cohort Study. *Epidemiol. Psychiatr. Sci.* 29, e142. doi:10.1017/S2045796020000542
- Johansen, A., Holmen, J., Stewart, R., and Bjerkeset, O. (2012). Anxiety and Depression Symptoms in Arterial Hypertension: the Influence of Antihypertensive Treatment. The HUNT Study, Norway. *Eur. J. Epidemiol.* 27 (1), 63–72. doi:10.1007/s10654-011-9641-y
- Kessing, L. V., Rytgaard, H. C., Ekstrøm, C. T., Torp-Pedersen, C., Berk, M., and Gerds, T. A. (2020). Antihypertensive Drugs and Risk of Depression: A Nationwide Population-Based Study. *Hypertension* 76 (4), 1263–1279. doi:10.1161/HYPERTENSIONAHA.120.15605

- Li, Z., Li, Y., Chen, L., Chen, P., and Hu, Y. (2015). Prevalence of Depression in Patients with Hypertension: A Systematic Review and Meta-Analysis. *Medicine* (*Baltimore*) 94 (31), e1317. doi:10.1097/MD.00000000001317
- Malhi, G. S., and Mann, J. J. (2018). Depression. *Lancet* 392 (10161), 2299–2312. doi:10.1016/S0140-6736(18)31948-2
- Michal, M., Wiltink, J., Lackner, K., Wild, P. S., Zwiener, I., Blettner, M., et al. (2013). Association of Hypertension with Depression in the Community: Results from the Gutenberg Health Study. J. Hypertens. 31 (5), 893–899. doi:10.1097/HJH.0b013e32835f5768
- Nasr, S. J., Crayton, J. W., Agarwal, B., Wendt, B., and Kora, R. (2011). Lower Frequency of Antidepressant Use in Patients on Renin-Angiotensin-Aldosterone System Modifying Medications. *Cell Mol Neurobiol* 31 (4), 615–618. doi:10.1007/s10571-011-9656-7
- Otte, C., Gold, S. M., Penninx, B. W., Pariante, C. M., Etkin, A., Fava, M., et al. (2016). Major Depressive Disorder. *Nat. Rev. Dis. Primers* 2, 16065. doi:10.1038/nrdp.2016.65
- Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., et al. (2021). The PRISMA 2020 Statement: an Updated Guideline for Reporting Systematic Reviews. *BMJ* 372, 372n71. doi:10.1136/bmj.n71
- Raič, M. (2017). Depression and Heart Diseases: Leading Health Problems. Psychiatr. Danub 29 (Suppl. 4), 770–777.
- Riemer, T. G., Villagomez Fuentes, L. E., Algharably, E. A. E., Schäfer, M. S., Mangelsen, E., Fürtig, M. A., et al. (2021). Do β-Blockers Cause Depression? Systematic Review and Meta-Analysis of Psychiatric Adverse Events during β-Blocker Therapy. *Hypertension* 77 (5), 1539–1548. doi:10.1161/ HYPERTENSIONAHA.120.16590
- Ringoir, L., Pedersen, S. S., Widdershoven, J. W., Pouwer, F., Keyzer, J. M., Romeijnders, A. C., et al. (2014). Beta-blockers and Depression in Elderly Hypertension Patients in Primary Care. *Fam. Med.* 46 (6), 447–453. doi:10.1517/14728222.2014.902938
- Rostom, A., Dubé, C., Cranney, A., Saloojee, N., Sy, R., Garritty, C., et al. (2004). *Celiac Disease. Evidence Reports/Technology Assessments.* Rockville, MD, USA: Agency for Healthcare Research and Quality. Available at: https://www.ncbi. nlm.nih.gov/books/NBK35156/.
- Rücker, G., and Schwarzer, G. (2015). Ranking Treatments in Frequentist Network Meta-Analysis Works without Resampling Methods. BMC Med. Res. Methodol. 15, 58. doi:10.1186/s12874-015-0060-8

- Simonson, W., Han, L. F., and Davidson, H. E. (2011). Hypertension Treatment and Outcomes in US Nursing Homes: Results from the US National Nursing Home Survey. J. Am. Med. Dir. Assoc. 12 (1), 44–49. doi:10.1016/j.jamda.2010.02.009
- Van de Velde, S., Bracke, P., and Levecque, K. (2010). Gender Differences in Depression in 23 European Countries. Cross-National Variation in the Gender gap in Depression. Soc. Sci. Med. 71 (2), 305–313. doi:10.1016/ j.socscimed.2010.03.035
- Wells, G. A., Shea, B., O'Connell, D., Peterson, J., Welch, V., Losos, M., et al. (2014). The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Available at: http://www.ohri.ca/ programs/clinical_epidemiology/oxford.asp. 2014.
- Yaniv, S. P., Lucki, A., Klein, E., and Ben-Shachar, D. (2010). Dexamethasone Enhances the Norepinephrine-Induced ERK/MAPK Intracellular Pathway Possibly via Dysregulation of the Alpha2-Adrenergic Receptor: Implications for Antidepressant Drug Mechanism of Action. *Eur. J. Cel Biol* 89 (9), 712–722. doi:10.1016/j.ejcb.2010.05.002
- Zhang, Y., Chen, Y., and Ma, L. (2018). Depression and Cardiovascular Disease in Elderly: Current Understanding. J. Clin. Neurosci. 47, 1–5. doi:10.1016/ j.jocn.2017.09.022

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Li, Fan, Sun, Alolga, Xiao and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.